<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H1E2F314A6AA94E329FCC161D2F920CCC" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 3658 IH: Gestational Diabetes Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-09-30</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 3658</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150930">September 30, 2015</action-date>
			<action-desc><sponsor name-id="E000179">Mr. Engel</sponsor> (for himself and <cosponsor name-id="B001248">Mr. Burgess</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To provide grants to better understand and reduce gestational diabetes, and for other purposes.</official-title>
	</form>
	<legis-body id="H6E5C0DCC0F2E40CFAC3DA0BD82A8E34E" style="OLC">
 <section id="HE0F16B7668A140F0A46D5C916ED5AE1D" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Gestational Diabetes Act of 2015</short-title></quote> or the <quote><short-title>GEDI Act</short-title></quote>.</text> </section><section id="H99E5EBC26B53463FB8784477137EAB81"><enum>2.</enum><header>Gestational diabetes</header><text display-inline="no-display-inline">Part B of title III of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/243">42 U.S.C. 243 et seq.</external-xref>) is amended by inserting after section 317H the following:</text>
			<quoted-block display-inline="no-display-inline" id="HA38310168C0C495799AF10D9BC3B4D78" style="OLC">
				<section id="H297DE0129D834610B4C98D89E7275171"><enum>317H–1.</enum><header>Gestational diabetes</header>
					<subsection id="HB06C8E2A6F834F378CB2E9BD8462D361"><enum>(a)</enum><header>Understanding and monitoring gestational diabetes</header>
 <paragraph id="H55ADAE8E94CB46F6A3124EF99F2FBCDE"><enum>(1)</enum><header>In general</header><text>The Secretary, acting through the Director of the Centers for Disease Control and Prevention, in consultation with the Diabetes Mellitus Interagency Coordinating Committee established under section 429 and representatives of appropriate national health organizations, shall develop a multisite gestational diabetes research project within the diabetes program of the Centers for Disease Control and Prevention to expand and enhance surveillance data and public health research on gestational diabetes.</text>
 </paragraph><paragraph id="HB313370502D74B62A5FA43DE72F49988"><enum>(2)</enum><header>Areas to be addressed</header><text>The research project developed under paragraph (1) shall address—</text> <subparagraph id="H5BEA4932A50148D8B1201A0951E39E62"><enum>(A)</enum><text>procedures to establish accurate and efficient systems for the collection of gestational diabetes data within each State and commonwealth, territory, or possession of the United States;</text>
 </subparagraph><subparagraph id="HA538B188DCFE4B8BA0E0E56BA42E9B21"><enum>(B)</enum><text>the progress of collaborative activities with the National Vital Statistics System, the National Center for Health Statistics, and State health departments with respect to the standard birth certificate, in order to improve surveillance of gestational diabetes;</text>
 </subparagraph><subparagraph id="HE0805B0B0DDD4B0DA82E1E484ACBAFD4"><enum>(C)</enum><text display-inline="yes-display-inline">postpartum methods of tracking women with gestational diabetes after delivery as well as targeted interventions proven to lower the incidence of type 2 diabetes in that population;</text>
 </subparagraph><subparagraph id="H516951762D454E5B94151CC6A36DA191"><enum>(D)</enum><text>variations in the distribution of diagnosed and undiagnosed gestational diabetes, and of impaired fasting glucose tolerance and impaired fasting glucose, within and among groups of women; and</text>
 </subparagraph><subparagraph id="HE5B9D33E0BDD4B84822B0FF0CC02240C"><enum>(E)</enum><text>factors and culturally sensitive interventions that influence risks and reduce the incidence of gestational diabetes and related complications during childbirth, including cultural, behavioral, racial, ethnic, geographic, demographic, socioeconomic, and genetic factors.</text>
 </subparagraph></paragraph><paragraph id="H8351B555989B4C9D925BD81AC46DA2C5"><enum>(3)</enum><header>Report</header><text>Not later than 2 years after the date of the enactment of this section, and annually thereafter, the Secretary shall generate a report on the findings and recommendations of the research project including prevalence of gestational diabetes in the multisite area and disseminate the report to the appropriate Federal and non-Federal agencies.</text>
						</paragraph></subsection><subsection id="H22D2E21705C84B8CB77D8D5578F62418"><enum>(b)</enum><header>Expansion of gestational diabetes research</header>
 <paragraph id="HEC512C09B82E432E8493DE90F0265162"><enum>(1)</enum><header>In General</header><text display-inline="yes-display-inline">The Secretary shall expand and intensify public health research regarding gestational diabetes. Such research may include—</text>
 <subparagraph id="HCCDCD130438B4E6DA1C95D8AF005FD31"><enum>(A)</enum><text>developing and testing novel approaches for improving postpartum diabetes testing or screening and for preventing type 2 diabetes in women with a history of gestational diabetes; and</text>
 </subparagraph><subparagraph id="HCC1A7865385844B587530C5CECEC7F4A"><enum>(B)</enum><text>conducting public health research to further understanding of the epidemiologic, socioenvironmental, behavioral, translation, and biomedical factors and health systems that influence the risk of gestational diabetes and the development of type 2 diabetes in women with a history of gestational diabetes.</text>
 </subparagraph></paragraph><paragraph id="HC9B73403C7A44A06AA3C718506B0C0EE"><enum>(2)</enum><header>Authorization of Appropriations</header><text>There is authorized to be appropriated to carry out this subsection $5,000,000 for each of fiscal years 2017 through 2021.</text>
						</paragraph></subsection><subsection id="H42769E139DB24B9490E09ACE6AE1BDBA"><enum>(c)</enum><header>Demonstration Grants To Lower the Rate of Gestational Diabetes</header>
 <paragraph id="HAB25479ED9624E2590FE28B3975CC789"><enum>(1)</enum><header>In General</header><text display-inline="yes-display-inline">The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall award grants, on a competitive basis, to eligible entities for demonstration projects that implement evidence-based interventions to reduce the incidence of gestational diabetes, the recurrence of gestational diabetes in subsequent pregnancies, and the development of type 2 diabetes in women with a history of gestational diabetes.</text>
 </paragraph><paragraph id="HE14569709E154BA0AACB6327273EA641"><enum>(2)</enum><header>Priority</header><text>In making grants under this subsection, the Secretary shall give priority to projects focusing on—</text> <subparagraph id="H228C9283377F47E0A92BE9F800E37BC6"><enum>(A)</enum><text display-inline="yes-display-inline">helping women who have 1 or more risk factors for developing gestational diabetes;</text>
 </subparagraph><subparagraph id="H28DF55551451459C97B05292FE249209"><enum>(B)</enum><text display-inline="yes-display-inline">working with women with a history of gestational diabetes during a previous pregnancy;</text> </subparagraph><subparagraph id="H6D3E9DAF6F8845269C48BC0EA275C217"><enum>(C)</enum><text display-inline="yes-display-inline">providing postpartum care for women with gestational diabetes;</text>
 </subparagraph><subparagraph id="H2FDACEC5E2174A59AADC6CD83AC88311"><enum>(D)</enum><text display-inline="yes-display-inline">tracking cases where women with a history of gestational diabetes developed type 2 diabetes;</text> </subparagraph><subparagraph id="H85FDFA10DDAB42F9B635010337933C3D"><enum>(E)</enum><text display-inline="yes-display-inline">educating mothers with a history of gestational diabetes about the increased risk of their child developing diabetes;</text>
 </subparagraph><subparagraph id="H1174C105496840D68036F5BA53F3C915"><enum>(F)</enum><text display-inline="yes-display-inline">working to prevent gestational diabetes and prevent or delay the development of type 2 diabetes in women with a history of gestational diabetes; and</text>
 </subparagraph><subparagraph id="HAA4F6033A9D3495281A995901498B469"><enum>(G)</enum><text display-inline="yes-display-inline">achieving outcomes designed to assess the efficacy and cost-effectiveness of interventions that can inform decisions on long-term sustainability, including third-party reimbursement.</text>
 </subparagraph></paragraph><paragraph id="HD983F4509D27441AB83D194756BA4ED9"><enum>(3)</enum><header>Application</header><text>An eligible entity desiring to receive a grant under this subsection shall submit to the Secretary—</text> <subparagraph id="HDB442654B19D4107B223AEDCEDCC3BEB"><enum>(A)</enum><text>an application at such time, in such manner, and containing such information as the Secretary may require; and</text>
 </subparagraph><subparagraph id="H137C495A9D2247969FD920C6F7DC6003"><enum>(B)</enum><text>a plan to—</text> <clause id="H90D4142FBD714C88B2EB369425CC1296"><enum>(i)</enum><text>lower the rate of gestational diabetes during pregnancy; or</text>
 </clause><clause id="H2AA379726C3E48D391A6DE3F9C33A381"><enum>(ii)</enum><text display-inline="yes-display-inline">develop methods of tracking women with a history of gestational diabetes and develop effective interventions to lower the incidence of the recurrence of gestational diabetes in subsequent pregnancies and the development of type 2 diabetes.</text>
 </clause></subparagraph></paragraph><paragraph id="H2B3DC96E62124C6A990B98FE498482BD"><enum>(4)</enum><header>Uses of Funds</header><text>An eligible entity receiving a grant under this subsection shall use the grant funds to carry out demonstration projects described in paragraph (1), including—</text>
 <subparagraph id="HAA492B9717054601ABD860A18D4C061A"><enum>(A)</enum><text>expanding community-based health promotion education, activities, and incentives focused on the prevention of gestational diabetes and development of type 2 diabetes in women with a history of gestational diabetes;</text>
 </subparagraph><subparagraph id="H8F9DCFF55BB546C4900C466DA15050D7"><enum>(B)</enum><text display-inline="yes-display-inline">aiding State- and tribal-based diabetes prevention and control programs to collect, analyze, disseminate, and report surveillance data on women with, and at risk for, gestational diabetes, the recurrence of gestational diabetes in subsequent pregnancies, and, for women with a history of gestational diabetes, the development of type 2 diabetes; and</text>
 </subparagraph><subparagraph id="H3E7526920C3343D0B2BB719C77F0B095"><enum>(C)</enum><text>training and encouraging health care providers—</text> <clause id="HF874FF67433441DFA0524B47D98C9E27"><enum>(i)</enum><text>to promote risk assessment, high-quality care, and self-management for gestational diabetes and the recurrence of gestational diabetes in subsequent pregnancies; and</text>
 </clause><clause id="HFCD5762AECDA4F22832EC9256955CCD0"><enum>(ii)</enum><text>to prevent the development of type 2 diabetes in women with a history of gestational diabetes, and its complications in the practice settings of the health care providers.</text>
 </clause></subparagraph></paragraph><paragraph id="H86F73D62D9584F3C904684F6E57212EA"><enum>(5)</enum><header>Report</header><text display-inline="yes-display-inline">Not later than 4 years after the date of the enactment of this section, the Secretary shall prepare and submit to the Congress a report concerning the results of the demonstration projects conducted through the grants awarded under this subsection.</text>
 </paragraph><paragraph id="HF9231AA00E4E4318807BC051FF8BF4C6"><enum>(6)</enum><header>Definition of Eligible Entity</header><text>In this subsection, the term <term>eligible entity</term> means a nonprofit organization (such as a nonprofit academic center or community health center) or a State, tribal, or local health agency.</text>
 </paragraph><paragraph id="HA2A305ED1BDA4C1F881CEFD1C68DE815"><enum>(7)</enum><header>Authorization of Appropriations</header><text>There is authorized to be appropriated to carry out this subsection $5,000,000 for each of fiscal years 2017 through 2021.</text>
 </paragraph></subsection><subsection id="HD613B1D6610C4760BEF221B4E13CC7E2"><enum>(d)</enum><header>Postpartum Follow-Up Regarding Gestational Diabetes</header><text>The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall work with the State- and tribal-based diabetes prevention and control programs assisted by the Centers to encourage postpartum follow-up after gestational diabetes, as medically appropriate, for the purpose of reducing the incidence of gestational diabetes, the recurrence of gestational diabetes in subsequent pregnancies, the development of type 2 diabetes in women with a history of gestational diabetes, and related complications.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
		</section></legis-body>
</bill>


